These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34053460)

  • 1. Acceptability of a COVID-19 pre-exposure prophylaxis trial with hydroxychloroquine in French healthcare workers during the first wave of COVID-19 pandemic.
    Gagneux-Brunon A; Schilte C; Garcin A; Jolly N; Vray M; Schaeffer L; Duval X; Hoen B; Botelho-Nevers E
    Trials; 2021 May; 22(1):373. PubMed ID: 34053460
    [No Abstract]   [Full Text] [Related]  

  • 2. Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Workers from India: A Meta-Analysis.
    Stricker RB; Fesler MC
    J Infect Public Health; 2021 Sep; 14(9):1161-1163. PubMed ID: 34391171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial.
    Rajasingham R; Bangdiwala AS; Nicol MR; Skipper CP; Pastick KA; Axelrod ML; Pullen MF; Nascene AA; Williams DA; Engen NW; Okafor EC; Rini BI; Mayer IA; McDonald EG; Lee TC; Li P; MacKenzie LJ; Balko JM; Dunlop SJ; Hullsiek KH; Boulware DR; Lofgren SM;
    Clin Infect Dis; 2021 Jun; 72(11):e835-e843. PubMed ID: 33068425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxychloroquine as pre-exposure prophylaxis against COVID-19 infection among healthcare workers: a prospective cohort study.
    Rao A; Veluswamy SK; Shankarappa BG; Reddy RM; Umesh N; John L; Mathew L; Shetty N
    Expert Rev Anti Infect Ther; 2022 May; 20(5):781-787. PubMed ID: 34865592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxychloroquine for Prevention of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: Challenges to Trial Conduct During the Global Pandemic.
    Goldman JD
    Clin Infect Dis; 2021 Jun; 72(11):e844-e847. PubMed ID: 33159196
    [No Abstract]   [Full Text] [Related]  

  • 6. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial.
    Grau-Pujol B; Camprubí-Ferrer D; Marti-Soler H; Fernández-Pardos M; Carreras-Abad C; Andrés MV; Ferrer E; Muelas-Fernandez M; Jullien S; Barilaro G; Ajanovic S; Vera I; Moreno L; Gonzalez-Redondo E; Cortes-Serra N; Roldán M; Arcos AA; Mur I; Domingo P; Garcia F; Guinovart C; Muñoz J
    Trials; 2021 Nov; 22(1):808. PubMed ID: 34781981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
    Mehta S; Bhandari S; Mehta S
    J Glob Antimicrob Resist; 2020 Sep; 22():864-865. PubMed ID: 32777441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.
    Abella BS; Jolkovsky EL; Biney BT; Uspal JE; Hyman MC; Frank I; Hensley SE; Gill S; Vogl DT; Maillard I; Babushok DV; Huang AC; Nasta SD; Walsh JC; Wiletyo EP; Gimotty PA; Milone MC; Amaravadi RK;
    JAMA Intern Med; 2021 Feb; 181(2):195-202. PubMed ID: 33001138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
    McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
    Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ).
    Naggie S; Milstone A; Castro M; Collins SP; Lakshmi S; Anderson DJ; Cahuayme-Zuniga L; Turner KB; Cohen LW; Currier J; Fraulo E; Friedland A; Garg J; George A; Mulder H; Olson RE; O'Brien EC; Rothman RL; Shenkman E; Shostak J; Woods CW; Anstrom KJ; Hernandez AF;
    Int J Infect Dis; 2023 Apr; 129():40-48. PubMed ID: 36682681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: early termination of a phase 3, randomised, open-label, controlled clinical trial.
    Llanos-Cuentas A; Schwalb A; Quintana JL; Delfin B; Alvarez F; Ugarte-Gil C; Guerra Gronerth RI; Lucchetti A; Grogl M; Gotuzzo E
    BMC Res Notes; 2023 Feb; 16(1):22. PubMed ID: 36849996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxychloroquine prophylaxis for SARS-CoV-2 infection among healthcare workers.
    R Karim HM; Ahmed G
    Indian J Med Res; 2020 Jul & Aug; 152(1 & 2):119-120. PubMed ID: 32773410
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serosurvey for Health-Care Workers Provides Supportive Evidence for the Effectiveness of Hydroxychloroquine Prophylaxis against SARS-CoV-2 Infection.
    Yadav RM; Pate A; Shankarkumar A; Athalye S; Shinde S; Bargir UA; Pate M; Ganpule M; Pruthi M; Patil H; Madkaikar MR
    J Epidemiol Glob Health; 2021 Sep; 11(3):283-288. PubMed ID: 34514761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials.
    Lewis K; Chaudhuri D; Alshamsi F; Carayannopoulos L; Dearness K; Chagla Z; Alhazzani W;
    PLoS One; 2021; 16(1):e0244778. PubMed ID: 33406138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of hydroxychloroquine for pre-exposure prophylaxis in COVID 19: debate and suggested future course.
    Agarwal M; Ranjan P; Mittal A; Baitha U
    Expert Rev Anti Infect Ther; 2021 Apr; 19(4):413-417. PubMed ID: 32981388
    [No Abstract]   [Full Text] [Related]  

  • 18. Cutaneous side effects of hydroxychloroquine in health care workers in a COVID referral hospital - implications for clinical practice.
    Sardana K; Mathachan SR; Deepak D; Khurana A; Sinha S
    J Dermatolog Treat; 2022 Mar; 33(2):1104-1106. PubMed ID: 32571115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.
    Principi N; Esposito S
    Lancet Infect Dis; 2020 Oct; 20(10):1118. PubMed ID: 32311322
    [No Abstract]   [Full Text] [Related]  

  • 20. Hydroxychloroquine prophylaxis for COVID-19 contacts in India.
    Rathi S; Ish P; Kalantri A; Kalantri S
    Lancet Infect Dis; 2020 Oct; 20(10):1118-1119. PubMed ID: 32311324
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.